January 27th, 2021
Presenter: Dr. Annabelle Biscans (AstraZeneca)
Small interfering RNAs (siRNAs) have the potential to revolutionize medicine due to their potency, duration of effect, and ability to target previously “undruggable” disease genes.
December 4th, 2020
At Intellia, we are building a full-spectrum, product-driven biotechnology company focused on our mission of developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
The purpose of this presentation is to formally introduce n-Lorem to OTS and to summarize progress since being founded in January 2020.
